Chemocentryx Stock News

A long, drawn out regulatory review weighed on the drugmaker's shares last year.

They're risky. But with the high risk comes the potential for high rewards.

ChemoCentryx's (CCXI) Tavneos gives a significant boost to the company, following its FDA approval in ANCA-associated vasculitis. The drug is also being evaluated in other indications.

ChemoCentryx Inc. (NASDAQ:CCXI) concluded the trading at $37.72 on Thursday, December 23 with a rise of 3.26% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $36.53 and 5Y monthly beta was reading 1.80 with its price kept floating in the range ChemoCentryx Inc. (CCXI) Outlook: Revisiting The Past For Future Insights Read More »

During the last session, ChemoCentryx Inc. (NASDAQ:CCXI)s traded shares were 6.65 million, with the beta value of the company hitting 1.79. At the end of the trading day, the stocks price was $34.38, reflecting an intraday gain of 1.30% or $0.44. The 52-week high for the CCXI share is $70.29, that puts it down -104.45 How Will ChemoCentryx Inc. (NASDAQ: CCXI) Look After It Drops -104.45% From Its Highs? Read More »

In the last trading session, 1.12 million ChemoCentryx Inc. (NASDAQ:CCXI) shares changed hands as the companys beta touched 1.81. With the companys per share price at $36.15 changed hands at $1.12 or 3.20% during last session, the market valuation stood at $2.71B. CCXIs last price was a discount, traded about -94.44% off its 52-week high ChemoCentryx Inc. (NASDAQ: CCXI) Stock Could Reward Investors With A -204.29% Loss Read More »

Morgan Stanley grew its stake in ChemoCentryx, Inc. (NASDAQ:CCXI) by 10.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 388,061 shares of the biopharmaceutical companys stock after buying an additional 35,607 shares during the period. Morgan Stanley owned 0.56% []

In last trading session, ChemoCentryx Inc. (NASDAQ:CCXI) saw 2.27 million shares changing hands with its beta currently measuring 1.80. Companys recent per share price level of $35.48 trading at -$0.8 or -2.21% at ring of the bell on the day assigns it a market valuation of $2.48B. That closing price of CCXIs stock is at ChemoCentryx Inc. (NASDAQ:CCXI) Has Made The 73.14% Recovery, Could Gain Another -98.11% Ahead Read More »

ChemoCentryx Inc. (NASDAQ:CCXI) traded at $36.28 at close of the session on Tuesday, 11/30/21, made a downward move of -1.68% on its previous days price. Looking at the stock we see that its previous close was $36.90 and the beta (5Y monthly) reads 1.44 with the days price range being $34.0058 $37.38. In terms ChemoCentryx Inc. (NASDAQ: CCXI) Drops -1.68%, Turning Investors Away Read More »

ChemoCentryx, Inc. (CCXI) with the stream of 1.71% also noticed, India Evolving Systems, Inc. (EVOL) encountered a rapid change of 0.00% in the last hour of Mondays trading session. ChemoCentryx, The post Alarming Stock: ChemoCentryx, Inc. (NASDAQ:CCXI), Evolving Systems, Inc. (NASDAQ:EVOL) appeared first on Stocks Equity .

Metropolitan Life Insurance Co NY raised its position in shares of ChemoCentryx, Inc. (NASDAQ:CCXI) by 107,064.3% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,003 shares of the biopharmaceutical companys stock after purchasing an additional 14,989 shares during the period. Metropolitan Life Insurance []

Brokerages predict that ChemoCentryx, Inc. (NASDAQ:CCXI) will report earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Six analysts have issued estimates for ChemoCentryxs earnings. The lowest EPS estimate is ($0.60) and the highest is $0.05. ChemoCentryx posted earnings per share of ($0.43) in the same quarter last year, which suggests []

ChemoCentryx Inc. (NASDAQ:CCXI)s traded shares stood at 0.54 million during the latest session, with the companys beta value hitting 1.80. At the last check today, the stocks price was $39.56, to imply an increase of 0.23% or $0.09 in intraday trading. The CCXI shares 52-week high remains $70.29, putting it -77.68% down since that peak ChemoCentryx Inc. (NASDAQ: CCXI) Has Succeeded In Gaining Momentum In 2021, The Stock Is Down -36.26% YTD Read More »

Shares of ChemoCentryx, Inc. (NASDAQ:CCXI) have received a consensus recommendation of Buy from the eight ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average []